HuL 217
Alternative Names: HL 217 - HuniLife Biotechnology; HuL-217Latest Information Update: 14 Nov 2025
At a glance
- Originator HuniLife Biotechnology
- Class Antifibrotics; Monoclonal antibodies
- Mechanism of Action ENO1 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
- Preclinical Pulmonary fibrosis
- Research Interstitial lung diseases
Most Recent Events
- 14 Nov 2025 Early research in Interstitial lung diseases in Taiwan (Parenteral), prior to November 2025 (HuniLife Biotechnology pipeline, November 2025)
- 14 Nov 2025 Phase-I clinical trials in Idiopathic pulmonary fibrosis (IV), prior to November 2025 (HuniLife Biotechnology pipeline, November 2025)
- 14 Nov 2025 Preclinical trials in Pulmonary fibrosis in Taiwan (Parenteral), prior to November 2025 (HuniLife Biotechnology pipeline, November 2025)